An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse [EXTENSION OF 700013353]
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2013
At a glance
- Drugs Farletuzumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Feb 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2009-015825-36).